Company: PSTV
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013256
Chunk: 34

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 34
---
 the relevant documents, which will remain binding on the Company.

Failure to obtain stockholder approval may materially adversely affect the Company’s future ability to raise equity or debt capital from third parties on attractive terms, if at all, and also risks significantly impairing the operations, assets and ongoing viability of the Company.

Additionally, if approval is not obtained at the Special Meeting, the Company will be obligated to continue to seek stockholder approval at least three times each year until stockholder approval is obtained.

#### Interests of Officers and Directors this Proposal
Our executive officers and directors who hold May 2024 Warrants have an interest in this Proposal No. 4 by virtue of their ownership of the May 2024 Warrants and the benefits conferred by extending the term of the May 2024 Warrants and potential economic gain received upon exercise thereof.

<div align='center'>20</div>

TABLE OF CONTENTS

The following table contains information relating to the ownership of May 2024 Warrants owned by our executive officers and directors, based on information as of April 9, 2025. As of that date, there were 3,093,708 May 2024 Warrants issued and outstanding.

| Name of Beneficial Owner(1) |     | Number of Shares of 
        Common Stock 
 Underlying May 2024 
      Warrants Owned |     | Percent Ownership of   
 Total Number of        
 Shares of Common Stock 
 Underlying Outstanding 
 May 2024 Warrants      |
| Marc H. Hedrick, M.D.(1)    |     |              12,255 |     | *                      |
| Andrew Sims(2)              |     |               4,902 |     | *                      |
| Howard Clowes(3)            |     |               9,804 |     | *                      |
| Richard J. Hawkins(4)       |     |               4,902 |     | *                      |
| Greg Petersen(5)            |     |              12,255 |     | *                      |
| Robert P. Lenk, PhD(6)      |     |               4,167 |     | *                      |

| * | Less than 1%. |

| (1) | Dr. Hedrick is the President, Chief Executive Officer and a director of the Company. |

| (2) | Mr. Sims is the Chief Financial Officer of the Company. |

| (3) | Mr. Clowes is a director of the Company